全文获取类型
收费全文 | 4611篇 |
免费 | 472篇 |
国内免费 | 4篇 |
出版年
2021年 | 62篇 |
2020年 | 45篇 |
2019年 | 41篇 |
2018年 | 49篇 |
2017年 | 44篇 |
2016年 | 106篇 |
2015年 | 200篇 |
2014年 | 223篇 |
2013年 | 260篇 |
2012年 | 314篇 |
2011年 | 315篇 |
2010年 | 213篇 |
2009年 | 193篇 |
2008年 | 231篇 |
2007年 | 263篇 |
2006年 | 252篇 |
2005年 | 246篇 |
2004年 | 229篇 |
2003年 | 203篇 |
2002年 | 217篇 |
2001年 | 76篇 |
2000年 | 77篇 |
1999年 | 57篇 |
1998年 | 65篇 |
1997年 | 42篇 |
1996年 | 49篇 |
1995年 | 45篇 |
1994年 | 23篇 |
1993年 | 48篇 |
1992年 | 65篇 |
1991年 | 65篇 |
1990年 | 42篇 |
1989年 | 51篇 |
1988年 | 44篇 |
1987年 | 42篇 |
1986年 | 47篇 |
1985年 | 29篇 |
1984年 | 44篇 |
1983年 | 38篇 |
1982年 | 39篇 |
1981年 | 36篇 |
1980年 | 25篇 |
1979年 | 24篇 |
1978年 | 23篇 |
1976年 | 24篇 |
1975年 | 23篇 |
1974年 | 17篇 |
1973年 | 20篇 |
1972年 | 24篇 |
1970年 | 21篇 |
排序方式: 共有5087条查询结果,搜索用时 112 毫秒
1.
Autoimmune destruction of the pancreatic islets in Type 1 diabetes is mediated by both increased proinflammatory (Teff) and decreased regulatory (Treg) T lymphocytes resulting in a significant decrease in the Treg:Teff ratio. The non-obese diabetic (NOD) mouse is an excellent in vivo model for testing potential therapeutics for attenuating the decrease in the Treg:Teff ratio and inhibiting disease pathogenesis. Here we show for the first time that a bioreactor manufactured therapeutic consisting of a complex of miRNA species (denoted as TA1) can effectively reset the NOD immune system from a proinflammatory to a tolerogenic state thus preventing or delaying autoimmune diabetes. Treatment of NOD mice with TA1 resulted in a systemic broad-spectrum upregulation of tolerogenic T cell subsets with a parallel downregulation of Teff subsets yielding a dramatic increase in the Treg:Teff ratio. Moreover, the murine-derived TA1 was highly effective in the inhibition of allorecognition of HLA-disparate human PBMC. TA1 demonstrated dose-responsiveness and exhibited equivalent or better inhibition of allorecognition driven proliferation than etanercept (a soluble TNF receptor). These findings demonstrate that miRNA-based therapeutics can effectively attenuate or arrest autoimmune disease processes and may be of significant utility in a broad range of autoimmune diseases including Type 1 diabetes. 相似文献
2.
3.
4.
Wendy Strahm 《Curtis's Botanical Magazine》1996,13(4):214-217
5.
The concepts of regulation and homeostasis are of frequent use but lack a single universally accepted definition. Here we propose a definition of theregulatory strength andhomeostatic strength, which allow to assess the importance of a regulatory pathway in a quantitative fashion. 相似文献
6.
7.
Second messengers are small rapidly diffusing molecules or ions that relay signals between receptors and effector proteins to produce a physiological effect. Lipid messengers constitute one of the four major classes of second messengers. The hydrolysis of two main classes of lipids, glycerophospholipids and sphingolipids, generate parallel profiles of lipid second messengers: phosphatidic acid (PA), diacylglycerol (DAG), and lysophosphatidic acid versus ceramide, ceramide-1-phosphate, sphingosine, and sphingosine-1-phosphate, respectively. In this review, we examine the mechanisms by which these lipid second messengers modulate aldosterone production at multiple levels. Aldosterone is a mineralocorticoid hormone responsible for maintaining fluid volume, electrolyte balance, and blood pressure homeostasis. Primary aldosteronism is a frequent endocrine cause of secondary hypertension. A thorough understanding of the signaling events regulating aldosterone biosynthesis may lead to the identification of novel therapeutic targets. The cumulative evidence in this literature emphasizes the critical roles of PA, DAG, and sphingolipid metabolites in aldosterone synthesis and secretion. However, it also highlights the gaps in our knowledge, such as the preference for phospholipase D-generated PA or DAG, as well as the need for further investigation to elucidate the precise mechanisms by which these lipid second messengers regulate optimal aldosterone production. 相似文献
8.
Wendy M Milne 《Australian Journal of Entomology》1999,38(2):145-147
The aphid parasitoid Aphidius ervi was released in the major lucerne-growing areas of New South Wales (NSW), Australia, between 1978 and 1981. With the collaboration of district agronomists of the New South Wales Department of Agriculture, five State-wide surveys were conducted in 1982–1983 to determine the success of the release program. In each survey, the distribution of the parasitoid was checked in relation to populations of the aphids Acyrthosiphon kondoi Shinji and Acyrthosiphon pisum (Harris) (Hemiptera: Aphididae). The surveys confirmed the successful dispersal and establishment of A. ervi in the major lucerne-growing areas of NSW. They demonstrated its ability to survive and recover rapidly after a severe and widespread drought. 相似文献
9.
10.